Nieuw oncologisch behandelprincipe met imatinib

Translated title of the contribution: Imatinib: New oncological treatment principle

B. C. Kuenen, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

One of the undoubted major breakthroughs in the recent treatment of cancer is imatinib, a tyrosine-kinase inhibitor of the bcr-ab1 fusion protein, the stem-cell factor receptor c-kit (KIT) and the platelet-derived growth-factor receptor. The successes obtained with imatinib in the treatment of chronic myeloid leukaemia (CML), gastrointestinal stroma-cell tumours (GIST), and dermatofibrosarcoma protuberans, demonstrate that targeted therapy with a rationally designed, small, synthetic molecule can be highly successful. However, experience so far with imatinib in KIT-positive tumours indicated that imatinib seems only to be effective in those tumours with a gain-of-function mutation in c-kit. There are arguments in favour of investigating a combined therapy of imatinib and classical chemotherapy.

Translated title of the contributionImatinib: New oncological treatment principle
Original languageDutch
Pages (from-to)2044-2045
Number of pages2
JournalNederlands Tijdschrift voor Geneeskunde
Volume147
Issue number42
StatePublished - Oct 18 2003
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Imatinib: New oncological treatment principle'. Together they form a unique fingerprint.

Cite this